Randomized Trial: Ibrutinib Regimens vs. Chemoimmunotherapy in Older Patients with Untreated CLL
3 Dec, 2018 | 23:39h | UTCCommentary: ASH 2018: Ibrutinib Alone or in Combination With Rituximab vs Bendamustine Plus Rituximab in Older Patients With CLL – The ASCO Post (free)